



Effect of Aspirin Dose on Preeclampsia Prevention and Fetal-maternal Complications: A Randomized Clinical Trial

Maryam Chamani¹, Saeid Shahrabi², Ali Malmir³ and Fereshteh Hassanzadeh^{4,*}

¹Department of Obstetrics and Gynecology, School of Medicine, Shahid Akbar-Abadi Hospital, Iran University of Medical Sciences, Tehran, Iran

²Department of Biochemistry and Hematology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran

³Department of Cell and Molecular Biology, Faculty of Life Science and Biotechnology, Shahid Beheshti University, Tehran, Iran

⁴Shahid Akbar-Abadi Hospital, Iran University of Medical of Sciences, Tehran, Iran

*Corresponding author: Shahid Akbar-Abadi Hospital, Iran University of Medical of Sciences, Tehran, Iran. Email: shamimmoghadas@gmail.com

Received 2021 May 30; Revised 2021 August 07; Accepted 2021 September 06.

Abstract

Background: Preeclampsia (PE) is a disease characterized by abnormalities in the placenta and endothelial cells. The pathogenesis is not fully understood; however, aspirin prescription can be effective to treat the disease and prevent fetal developmental disorders.

Methods: This study was performed as a clinical trial in Shahid Akbrabadi Hospital in Tehran city. Eighty patients participated in two groups (n = 40). The first group of patients received the dose of 80 mg, and the second group received the dose of 160 mg aspirin. Then, the fetal-maternal and treatment process complications were examined in the patients.

Results: The results showed that the incidence of fetal-maternal complications, including intrauterine growth restriction (IUGR) and intrauterine fetal death (IUFD) was lower in patients treated with 160 mg aspirin than in the other group, but this difference was not statistically significant (P-value > 0.05). Aspirin complications such as bleeding were more in the second group than in the first one (P-value < 0.05).

Conclusions: Although the increasing dose of aspirin reduces fetal-maternal complications in PE patients, the problems such as aspirin-induced bleeding should be considered.

Keywords: Aspirin, Preeclampsia, Fetus, Mother, Complication

1. Background

Preeclampsia (PE) is a pregnancy disorder usually diagnosed with high blood pressure (systolic blood pressure \geq 140 mmHg and diastolic blood pressure \geq 90 mmHg) and proteinuria after the 20th week of pregnancy. Preeclampsia diagnosis is difficult in patients with chronic diseases, who suffer from high blood pressure or proteinuria at the same time. It can also lead to eclampsia, kidney and liver dysfunction, and coagulation system abnormalities (1-3).

Preeclampsia and fetal growth restriction (FGR) are the most important causes of perinatal death and complications in survivors, especially the increased risk of cardiovascular disease in mothers and newborns (4, 5). The risk of developing these complications increases in the presence of severe diseases, and may lead to preterm labor (PTL) before the 37th week of gestation (6, 7). Preeclampsia occurs in 1-8% of pregnant women on average, and its prevalence varies in different countries due to various risk factors. Overall, this disorder is the second leading cause of maternal mortality in the world (1, 8).

Some PE treatments include pregnancy termination, antihypertensive drugs, magnesium sulfate, beta-blockers, calcium channel blockers, and aspirin (9). Nowadays, aspirin is used as a treatment for PE. For this purpose, a study by Rolnik et al. showed that the use of aspirin in PE patients could be associated with a reduction in maternal and fetal complications (6, 10). Also, Wright and Nicolaides's study showed that the use of aspirin prevented the progression of PE and improved the clinical condition of mother and fetus (11).

Thromboxane A₂ (TXA₂), which is responsible for vasoconstriction and platelet aggregation, increases in PE while prostacyclin, which mediates vasodilation and inhibits platelet aggregation, decreases, which are associated with increased risk of thrombosis in patients. Aspirin prevents this disorder by inhibiting the TXA₂ secretion without affecting prostacyclin secretion. Therefore, the use of aspirin in patients can prevent thrombosis and placental abruption (1, 12-14).

2. Objectives

Due to the challenging results associated with PE treatment with aspirin and also very few studies about the effect of different doses of aspirin on the treatment process, we decided to evaluate the effect of different doses of aspirin on PE treatment.

3. Methods

This one-sided randomized clinical trial was done in Shahid Akbarabadi Medical Center during 2018-2019. The study was approved by the Ethics Committee of Iran University of Medical Sciences (IR.IUMS.FMD.REC.1398.133) and registered in the Iranian Clinical Trial Center (IRCT20190826044619N1). A simple convenience sampling method was utilized in this study. All pregnant women with a gestational age of 12-16 weeks, who had been referred to the hospital's prenatal clinic, were selected for the study. Patients were randomly assigned to the study groups (40 people in each group) based on block randomization with computer software. The first group received aspirin with the dose of 80 mg and the second group received the dose of 160 mg.

The inclusion criteria included pregnancy at 12 - 16 weeks of gestation, previous history of PE, diabetes, hypertension, and multipara. The exclusion criteria included the occurrence of problems and complications due to drug consumption (drug intolerance and gastric bleeding), subcutaneous bleeding, and platelet depletion.

At the first visit, demographic characteristics including age, body mass index (BMI), number of pregnancies, and systolic and diastolic blood pressures were recorded. Pregnant mothers were visited every two weeks until the 28th week of pregnancy, and then weekly until the end of the pregnancy. The drug consumption continued for 36 weeks and was then discontinued. Individuals, who developed blood pressure ≥ 140.90 mm Hg, proteinuria $> +1$ during a urine strip test, or proteinuria > 300 mg in 24-h urine during pregnancy, were monitored. Based on the PE severity, necessary measures were taken to terminate or continue the pregnancy.

If fetal intrauterine growth disorder was suspected, a Doppler ultrasound of the umbilical artery, midbrain, and venous duct was performed to confirm or rule out the fetal intrauterine growth restriction (IUGR). All subjects were monitored until the end of pregnancy. Pregnancy outcomes including PE, fetal IUGR, PTL, and delivery method were recorded. After birth, the Apgar score at first and fifth minutes and the weight of the infant were also recorded.

3.1. Statistical Analysis

After data collection using a questionnaire, the information was coded and entered into the computer. We used SPSS V.22 software for data analysis. An independent *t* test was performed to compare the continuous variables. The chi-square and the Fisher tests were also applied for qualitative variables. Logistic regression was also used to estimate the odds ratio of the effect. For each test, a *P* value < 0.05 was considered statistically significant.

4. Result

4.1. Demographical Information

The final analysis was performed on 80 pregnant women in two groups ($n = 40$ in each group), with the aspirin dose of 80 mg (first group) and 160 mg (second group). The overall participants' mean age was 32.3 ± 7.1 , which was 32.4 ± 6.9 in the first group and 32.3 ± 7.4 in the second group; there was no significant difference between the two groups. In terms of education level, a significant difference was observed between the two groups (*P* value = 0.04). The causes of delivery such as the rupture of membranes (ROM), labor pain (LP), PTL, and other cases were higher in the second group than in the first group; this difference was not statistically significant (*P* value = 0.05). There was no significant difference between the two groups in terms of delivery type (normal vs. cesarean section), smoking, and type of occupation (Table 1).

4.2. Pregnancy Complications

The complications of previous pregnancy, as well as those caused by aspirin consumption, were evaluated in the two groups. Based on the results, the complications of previous pregnancies such as PE, intrauterine fetal death (IUFD), and premature ROM (PROM) were higher in the first group; this difference was not statistically significant. Also, pregnancy complications due to aspirin consumption such as PE, hypertension, and diabetes were higher in the first group; this difference was not statistically significant, too (Table 2).

4.3. Fetus Complications

The previous history of fetal complications, as well as fetal complications due to aspirin use, was examined in both groups. The results showed that the incidence of IUGR and IUFD complications was higher in the first group, but no statistically significant difference was observed between them (Table 3).

Table 1. Demographic Information in Two Groups with Aspirin Consumption of 80 and 160 mg^a

Variable	Aspirin Dose 80 mg (n = 40)	Aspirin Dose 160 mg (n = 40)	P Value ^b
Age	32.4 ± 6.9	32.3 ± 7.4	0.82
Height	160.8 ± 4.9	164.07 ± 7.11	0.03
Maternal weight	71.5 ± 18.4	70.67 ± 12.9	0.15
BMI	27.5 ± 6.7	26.4 ± 4.7	0.18
Fetal weight	37.1 ± 2.1	37.05 ± 2.03	0.86
Smoking			0.30
Yes	1 (2.5)	3 (7.5)	
No	39 (97.5)	37 (92.5)	
Childbirth			0.36
Natural	16(40)	20(50)	
Cesarean section	24(60)	20(50)	
Apgar 1 (8)	2(5)	0(0)	0.1
Apgar 5 (9)	38(95)	40(100)	0.1
Education			0.04
Illiterate	1(2.5)	0 (0)	
Primary	2 (5)	7(17.5)	
High school	16 (40)	6 (15)	
Diploma	17 (42)	24 (60)	
Academic	4 (10)	3 (7.5)	
Profession			0.15
Housewife	38 (95)	40 (100)	
Manual worker	2 (5)	0 (0)	
Cause of childbirth			0.05
LP	4 (10)	8 (20)	
ROM	4 (10)	8 (20)	
Pain	3 (7.5)	3 (7.5)	
PTL	0 (0)	6 (15)	
Fetal movement	1(2.5)	1 (2.5)	
Twin	3 (7.5)	0 (0)	
IUGR	1 (2.5)	1 (2.5)	
Heart arrest	1 (2.5)	0 (0)	
Preeclampsia	4 (10)	0 (0)	
RII	3 (7.5)	0 (0)	
Prolapse	1 (2.5)	0 (0)	
Other	10 (25)	9 (22.5)	
Combination ^c	5 (12.5)	4 (10)	

Abbreviations: BMI, body mass index; Lp, labor pain; ROM, rupture of membrane; PTL, preterm Labor; IUGR, intrauterine growth restriction; RII, repeat II.

^a Values are expressed as No. (%).

^b P value was calculated by chi-square or *t* test.

^c Combination involved LP, ROM, pain, PTL, IUGR, and RII. Prolapse: the state when the umbilical cord comes out of the uterus, with or before the presenting part of the baby.

Table 2. Evaluation of Pregnancy Complications in Two Groups^a

	Aspirin Dose 80 mg	Aspirin Dose 160 mg	OR (CI)	P Value ^b
Present pregnancy complications				
Preeclampsia	5 (12.5)	1 (2.5)	0.17 (0.003 - 1.7)	0.08
Hypertension	4 (10)	3 (7.5)	0.7 (0.1 - 4.6)	0.6
Diabetes	7 (17.5)	2 (5)	0.2 (0.2 - 1.4)	0.07
Combination	5 (12.5)	2 (5)	0.4 (0.4 - 3.1)	0.3
Previous pregnancy complications				
Preeclampsia	7 (17.5)	5 (12.5)	0.6 (0.1 - 2.7)	0.5
IUFD	2 (5)	0	-	0.15
PROM	3 (7.5)	0	-	0.07
Other	21 (52.5)	0	-	< 0.001

Abbreviations: IUFD, intrauterine fetal death; PROM, premature rupture of membrane.

^aValues are expressed as No. (%) unless otherwise indicated.

^bP-value was calculated by chi-square or *t* test.

Table 3. Aspirin-derived Fetus Complications in Two Groups^a

	Aspirin Dose 80 mg	Aspirin Dose 160 mg	OR (CI)	P Value ^b
Present Fetal Complications				
IUGR	5 (12.5)	3 (7.5)	0.5 (0.8 - 3.1)	0.4
IUFD	3 (7.5)	0 (0)	-	0.07
Previous fetal complications				
IUGR	2 (5)	1 (2.5)	0.4 (0.08 - 9.8)	0.5
IUFD	1 (2.5)	0 (0)	-	0.3
Other	0 (0)	1 (2.5)	-	0.3

Abbreviations: IUGR, intrauterine growth restriction; IUFD, intrauterine fetal death.

^aValues are expressed as No. (%) unless otherwise indicated.

^bP value was calculated by chi-square and *t* test.

4.4. Aspirin-derived Complications

Regarding the incidence of aspirin-related complications, the first group showed more wound infection, pain, and HIT, while the second group showed more hemorrhagic, gastrointestinal, and respiratory complications (P-value:0.01). Thus, there was a significant difference between the two groups in terms of aspirin-related complications (Table 4).

5. Discussion

Preeclampsia is one of the leading causes of maternal and perinatal mortality, with a prevalence of approximately 8% worldwide. It is characterized by placental abruption, high blood pressure, and proteinuria (15). High blood pressure can affect fetus development and lead to pregnancy disorders and complications such as premature birth and even fetal death. In addition, it has been

shown that PE can be associated with some diseases and complications in the mother and fetus, including diabetes and cardiovascular diseases (16). Depending on the pathogenesis and progression of PE, it is divided into subgroups. Placental dysfunction can be one of the main causes of disease, which leads to disorders in the relationship between the mother and fetus.

Although many therapeutic strategies have been considered for PE treatment, due to the unknown pathogenesis of the disease, the main treatment has not been identified yet (17). Aspirin is one of the drugs, which is used to treat PE. Previous studies have shown challenging results regarding the effect of aspirin on PE treatment. However, very few studies have been performed on aspirin dose and its effect on PE treatment.

A study by Zhang et al. found that the incidence of maternal complications, including the recurrence of PE, diabetes, and hypertension, was higher in patients receiving

Table 4. Aspirin-derived Complications in Two Groups^a

Aspirin-derived Complications	Aspirin Dose 80 mg	Aspirin Dose 160 mg	P Value ^b
Bleeding	0 (0)	2 (5)	0.01
Gastrointestinal complications	0 (0)	4 (10)	
Respiratory complications	0 (0)	3 (7.5)	
Wound infection	3 (7.5)	0 (0)	
Pain	1 (2.5)	0 (0)	
HIT	1 (2.5)	0 (0)	
Other	0 (0)	3 (7.5)	
Combination ^c	1(2.5)	2 (5)	

Abbreviation: HIT, heparin-induced thrombocytopenia.

^aValues are expressed as No. (%).

^bP value was calculated by chi-square or *t* test.

^cCombination involved bleeding, gastrointestinal complications, respiratory complications, wound infection, pain, and PIT.

aspirin than in controls. These results indicated that aspirin consumption in patients could not play a protective role against PE recurrence (18). Another study by Ling et al. reported a reduced incidence of maternal complications due to aspirin consumption; the cited complications included PE, diabetes, and heart disease, which were statistically significant in PE patients (19).

The present study showed that the incidence of maternal complications such as diabetes, hypertension, and PE was higher in the group receiving 80 mg aspirin than in the group receiving 160 mg, but this difference was not statistically significant. Although the incidence of maternal complications decreased with increasing aspirin dosage, the lack of significant correlation could be due to the low sample size, which needs to be evaluated in a larger number of patients in future studies.

Fetal complications are another factor that can be prevented by aspirin prescription in PE patients. A study by Abdi et al. declared that the use of aspirin reduced the incidence of complications such as IUGR (20). Vanda et al. showed that the use of aspirin (80 mg) reduced maternal and fetal complications in PE mothers (21). The present study also suggested that increasing aspirin dosage would prevent complications such as IUGR and IUFD.

A study by Hastie et al. also reported bleeding as a result of aspirin consumption during pregnancy (22). This study also showed that the aspirin side effects, including bleeding, were higher at the dose of 160 mg, which was statistically significant.

5.1. Conclusions

It can be concluded that increasing aspirin dosage reduces the incidence of maternal and fetal complications in PE mothers. It should be noted that bleeding is one of

the side effects of aspirin. The monitoring of patients during treatment procedures should be considered to prevent possible bleeding.

Acknowledgments

We wish to thank all our colleagues at Iran University of Medical Sciences.

Footnotes

Authors' Contribution: F. H. conceived the study and revised the manuscript. M. Ch wrote the manuscript. A.M revised the manuscript and S. Sh was native English editor.

Clinical Trial Registration Code: The study was registered in the Iranian Clinical Trial Center (IRCT20190826044619N1).

Conflict of Interests: The authors declare no conflict of interest.

Ethical Approval: The study was approved by the Ethics Committee of Iran University of Medical Sciences (IR.IUMS.FMD.REC.1398.133).

Funding/Support: This work was financially supported by grant 2763 from the Vice Chancellor for Research Affairs of Iran University of Medical Sciences, Tehran, Iran.

Informed Consent: Informed consent was obtained from all patients participating in this study.

References

- Atallah A, Lecarpentier E, Goffinet F, Doret-Dion M, Gaucherand P, Tsatsaris V. Aspirin for Prevention of Preeclampsia. *Drugs*. 2017;77(17):1819–31. doi: 10.1007/s40265-017-0823-0. [PubMed: 29039130]. [PubMed Central: PMC5681618].

2. Kattah AG, Garovic VD. The management of hypertension in pregnancy. *Adv Chronic Kidney Dis.* 2013;**20**(3):229–39. doi: [10.1053/j.ackd.2013.01.014](https://doi.org/10.1053/j.ackd.2013.01.014). [PubMed: [23928387](https://pubmed.ncbi.nlm.nih.gov/23928387/)]. [PubMed Central: [PMC3925675](https://pubmed.ncbi.nlm.nih.gov/PMC3925675/)].
3. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, Paris Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. *Lancet.* 2007;**369**(9575):1791–8. doi: [10.1016/S0140-6736\(07\)60712-0](https://doi.org/10.1016/S0140-6736(07)60712-0). [PubMed: [17512048](https://pubmed.ncbi.nlm.nih.gov/17512048/)].
4. Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. *Am J Obstet Gynecol.* 2017;**216**(2):110–120 e6. doi: [10.1016/j.ajog.2016.09.076](https://doi.org/10.1016/j.ajog.2016.09.076). [PubMed: [27640943](https://pubmed.ncbi.nlm.nih.gov/27640943/)].
5. Pouladzadeh M, Safdarian M, Eshghi P, Abolghasemi H, Bavani AG, Sheibani B, et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. *Intern Emerg Med.* 2021;**16**(8):2181–91. doi: [10.1007/s11739-021-02734-8](https://doi.org/10.1007/s11739-021-02734-8). [PubMed: [33837906](https://pubmed.ncbi.nlm.nih.gov/33837906/)]. [PubMed Central: [PMC8035885](https://pubmed.ncbi.nlm.nih.gov/PMC8035885/)].
6. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matalana C, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. *N Engl J Med.* 2017;**377**(7):613–22. doi: [10.1056/NEJMoa1704559](https://doi.org/10.1056/NEJMoa1704559). [PubMed: [28657417](https://pubmed.ncbi.nlm.nih.gov/28657417/)].
7. Pouladzadeh M, Safdarian M, Choghakabodi PM, Amini F, Sokooti A. Validation of red cell distribution width as a COVID-19 severity screening tool. *Future Sci OA.* 2021;**7**(7):FSO712. doi: [10.2144/foa-2020-0199](https://doi.org/10.2144/foa-2020-0199). [PubMed: [34254030](https://pubmed.ncbi.nlm.nih.gov/34254030/)]. [PubMed Central: [PMC8056748](https://pubmed.ncbi.nlm.nih.gov/PMC8056748/)].
8. von Dadelszen P, Magee LA. Pre-eclampsia: an update. *Curr Hypertens Rep.* 2014;**16**(8):454. doi: [10.1007/s11906-014-0454-8](https://doi.org/10.1007/s11906-014-0454-8). [PubMed: [24915961](https://pubmed.ncbi.nlm.nih.gov/24915961/)].
9. Berzan E, Doyle R, Brown CM. Treatment of preeclampsia: current approach and future perspectives. *Curr Hypertens Rep.* 2014;**16**(9):473. doi: [10.1007/s11906-014-0473-5](https://doi.org/10.1007/s11906-014-0473-5). [PubMed: [25135649](https://pubmed.ncbi.nlm.nih.gov/25135649/)].
10. Rajaei E, Shahbazian N, Rezaeeyan H, Mohammadi AK, Hesam S, Zayeri ZD. The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014. *Clin Rheumatol.* 2019;**38**(11):3211–5. doi: [10.1007/s10067-019-04682-3](https://doi.org/10.1007/s10067-019-04682-3). [PubMed: [31352646](https://pubmed.ncbi.nlm.nih.gov/31352646/)].
11. Wright D, Nicolaides KH. Aspirin delays the development of preeclampsia. *Am J Obstet Gynecol.* 2019;**220**(6):580 e1–6. doi: [10.1016/j.ajog.2019.02.034](https://doi.org/10.1016/j.ajog.2019.02.034). [PubMed: [30797761](https://pubmed.ncbi.nlm.nih.gov/30797761/)].
12. Smith WL. The eicosanoids and their biochemical mechanisms of action. *Biochem J.* 1989;**259**(2):315. doi: [10.1042/bj2590315](https://doi.org/10.1042/bj2590315). [PubMed: [2655580](https://pubmed.ncbi.nlm.nih.gov/2655580/)].
13. Perneby C, Vahter M, Akesson A, Bremme K, Hjemdahl P. Thromboxane metabolite excretion during pregnancy—influence of preeclampsia and aspirin treatment. *Thromb Res.* 2011;**127**(6):605–6. doi: [10.1016/j.thromres.2011.01.005](https://doi.org/10.1016/j.thromres.2011.01.005). [PubMed: [21316743](https://pubmed.ncbi.nlm.nih.gov/21316743/)].
14. Feizollahi N, Zayeri ZD, Moradi N, Zargar M, Rezaeeyan H. The effect of coagulation factors polymorphisms on abortion. *Front Biol.* 2018;**13**(3):190–6. doi: [10.1007/s11515-018-1500-8](https://doi.org/10.1007/s11515-018-1500-8).
15. Hladunewich M, Karumanchi SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. *Clin J Am Soc Nephrol.* 2007;**2**(3):543–9. doi: [10.2215/CJN.03761106](https://doi.org/10.2215/CJN.03761106). [PubMed: [17699462](https://pubmed.ncbi.nlm.nih.gov/17699462/)].
16. El-Sayed AAF. Preeclampsia: A review of the pathogenesis and possible management strategies based on its pathophysiological derangements. *Taiwan J Obstet Gynecol.* 2017;**56**(5):593–8. doi: [10.1016/j.tjog.2017.08.004](https://doi.org/10.1016/j.tjog.2017.08.004). [PubMed: [29037542](https://pubmed.ncbi.nlm.nih.gov/29037542/)].
17. McCoy S, Baldwin K. Pharmacotherapeutic options for the treatment of preeclampsia. *Am J Health Syst Pharm.* 2009;**66**(4):337–44. doi: [10.2146/ajhp080104](https://doi.org/10.2146/ajhp080104). [PubMed: [19202042](https://pubmed.ncbi.nlm.nih.gov/19202042/)].
18. Zhang Y, Shen F, Yang W, Wang J, Zhou J, Chen Y. Effects of low-molecular-weight heparin and aspirin in recurrent pre-eclampsia: A stratified cohort study. *Int J Gynaecol Obstet.* 2021;**154**(2):337–42. doi: [10.1002/ijgo.13535](https://doi.org/10.1002/ijgo.13535). [PubMed: [33314052](https://pubmed.ncbi.nlm.nih.gov/33314052/)].
19. Ling HZ, Jara PG, Bisquera A, Poon LC, Nicolaides KH, Kametas NA. Maternal cardiac function in women at high risk for pre-eclampsia treated with 150 mg aspirin or placebo: an observational study. *BJOG.* 2020;**127**(8):1018–25. doi: [10.1111/1471-0528.16193](https://doi.org/10.1111/1471-0528.16193). [PubMed: [32133780](https://pubmed.ncbi.nlm.nih.gov/32133780/)].
20. Abdi N, Rozrokh A, Alavi A, Zare S, Vafaei H, Asadi N, et al. The effect of aspirin on preeclampsia, intrauterine growth restriction and preterm delivery among healthy pregnancies with a history of preeclampsia. *J Chin Med Assoc.* 2020;**83**(9):852–7. doi: [10.1097/JCMA.0000000000000400](https://doi.org/10.1097/JCMA.0000000000000400). [PubMed: [32773581](https://pubmed.ncbi.nlm.nih.gov/32773581/)]. [PubMed Central: [PMC7478204](https://pubmed.ncbi.nlm.nih.gov/PMC7478204/)].
21. Vanda R, Aramesh S, Sadeghian M, Ghatee MA, Ghaffari P. Effect of Aspirin on Pre-eclampsia and Fetal Growth Restriction in Obese Pregnant Women: A Randomized Controlled Clinical Trial. *J Clin Care Skills.* 2020;**1**(4):159–64. doi: [10.52547/jccs.1.4.159](https://doi.org/10.52547/jccs.1.4.159).
22. Hastie R, Tong S, Wikstrom AK, Sandstrom A, Hesselman S, Bergman L. Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study. *Am J Obstet Gynecol.* 2021;**224**(1):95 e1–95 e12. doi: [10.1016/j.ajog.2020.07.023](https://doi.org/10.1016/j.ajog.2020.07.023). [PubMed: [32687818](https://pubmed.ncbi.nlm.nih.gov/32687818/)].